



**OnPAR and Open Therapeutics Partner for Enhancing the Flow of Grants to Researchers**  
*Will collaborate to help scientists gain funding for previously highly rated but unfunded proposals.*

Reston, VA and Minneapolis, MN – January 23, 2018 – Leidos welcomes Open Therapeutics to OnPAR, the Online Partnership to Accelerate Research. OnPAR, originally launched by the Leidos Life Sciences team in March 2016, is a partnership with the National Institutes of Health (NIH) that offers a new funding paradigm with the goal of matching highly scored, unfunded applications with potential non-government organizations. OnPAR is expanding globally, and has received applications from 16 countries and over 40 funding agencies.

The OnPAR public-private partnership provides a second opportunity for promising, unfunded research proposals. High-quality, high-scoring research applications that were originally submitted and not funded will be matched for potential funding with a participating organization member's specialized area of interest. Members include private foundations, such as the Breast Cancer Research Foundation, Cystinosis Research Foundation, and Cure Alzheimer's Fund, as well as pharmaceutical companies, i.e., Daiichi Sankyo and Eli Lilly. Others will be joining soon.

Open Therapeutics will integrate OnPAR into its global research collaboration platform, Therapoid™. Open Therapeutics issues requests for proposals (RFPs) that often result in highly rated but unfunded proposals, which will be provided to OnPAR. Open Therapeutics helps researchers around the world gain scientific collaborators, particularly scientists from the underserved areas of Africa, Asia (China, India), and Latin America. Therapoid, the open-science collaborative ecosystem, is a free web-based platform that crowdsources researchers around open therapeutic technologies. Included free services include prepeer reviews and preprint servers.

“We welcome Open Therapeutics to OnPAR,” says Martin Dueñas, Director, Health Research Management Practice, Leidos Life Sciences. “OnPAR seeks to accelerate research discovery to improve lives for people around the world by providing research investigators a second opportunity for funding without re-writing a new application. Therapoid is in sync with OnPAR’s goal by providing an open platform that allows for scientific collaboration for therapeutic discovery, development, and delivery that will accelerate medicines to patients.”

According to Jason E. Barkeloo, Founder and Executive Chairman of Open Therapeutics, “OnPAR has a proven ability to facilitate researchers gaining a second chance for funding. Our researchers invest time into developing proposals. We are excited to help the scientific community gain access to the important OnPAR service!”

**About Open Therapeutics LLC**

Open Therapeutics (<http://OpenTherapeutics.org>) is a crowdsourcing life science firm that creates and attracts therapeutic biotechnologies and crowdsources them for the global scientific community. The global research community can freely access the biotechnologies and funding to further the development of the biotechnologies at *Therapoid*™ (<https://Therapoid.net>). The Company is headquartered in Minneapolis, MN, with laboratory operations in Covington, Kentucky, Cincinnati, OH, Amman, Jordan, and Bangalore, India.

**Contact:** Jerome Hamilton, CEO, Open Therapeutics  
+1 (651) 900-0412  
OpenTherapeutics.org  
@OpenTherapeutic

**About Leidos**

Leidos is a Fortune 500® science and technology solutions and services leader working to solve the world’s toughest challenges in the defense, intelligence, homeland security, civil, and health markets. The company’s 32,000 employees support vital missions for government and commercial customers. Headquartered in Reston, Virginia, Leidos reported annual revenues of approximately \$7.04 billion for the fiscal year ended December 30, 2016. For more information, visit [www.Leidos.com](http://www.Leidos.com).

###

